FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

17 letters match. Newest first.

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  3. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  4. Eurofins SF Analytical Laboratories, Inc.

    FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

    High risk
  5. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  6. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  7. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  8. Safrel Pharmaceuticals LLC

    FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.

    High risk
  9. Genzyme Ireland Limited

    Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.

    High risk
  10. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  11. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  12. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  13. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  14. Chemco Corporation

    FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.

    High risk
  15. Microbiological Testing & Consulting, LLC

    FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.

    High risk
  16. AQ USA Inc., d.b.a Ross Healthcare Inc.

    FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

    High risk
  17. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk